At-Home Infectious Disease Test Developer Lucira Health Goes Public at $17 Per Share

Feb 05, 2021

|

NEW YORK — Lucira Health went public on Friday as its shares began trading on the Nasdaq for $17 per share under ticker symbol LHDX.

The Emeryville, California-based company late on Thursday priced its upsized initial public offering of 9,000,000 shares of common stock at $17 per share for anticipated gross proceeds of $153 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

At-Home Infectious Disease Test Developer Lucira Health Goes Public at $17 Per Share

To read the full story....

Breaking News

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

What's Popular?

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Ortho Clinical Diagnostics Gets Additional CE Mark for Coronavirus Antigen Test

Sponsorships